{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:18:16Z","timestamp":1793409496355,"version":"4.5.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e0 degli Studi di Roma La Sapienza"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s43440-026-00830-0","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T14:22:43Z","timestamp":1771856563000},"page":"627-640","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Rifaximin\u2019s therapeutic spectrum: approved indications and experimental insights into emerging uses"],"prefix":"10.1007","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5019-653X","authenticated-orcid":false,"given":"Irene","family":"Palenca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7114-9089","authenticated-orcid":false,"given":"Silvia Basili","family":"Franzin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5996-4259","authenticated-orcid":false,"given":"Marcella","family":"Pesce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1467-1134","authenticated-orcid":false,"given":"Giovanni","family":"Sarnelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8080-8218","authenticated-orcid":false,"given":"Giuseppe","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"issue":"7","key":"830_CR1","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1080\/17425255.2018.1488964","volume":"14","author":"E Bruzzese","year":"2018","unstructured":"Bruzzese E, Pesce M, Sarnelli G, Guarino A. Pharmacokinetic drug evaluation of rifaximin for treatment of diarrhea-predominant irritable bowel syndrome. Expert Opin Drug Metab Toxicol. 2018;14(7):753\u201360. Epub 2018 Jun 22. PMID: 29897844.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3","key":"830_CR2","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3390\/antibiotics12030443","volume":"12","author":"A Piccin","year":"2023","unstructured":"Piccin A, Gulotta M, di Bella S, Martingano P, Croce LS, Giufre M. Diverticular disease and rifaximin: an evidence-based review. Antibiot (Basel). 2023;12(3):443.","journal-title":"Antibiot (Basel)"},{"issue":"8","key":"830_CR3","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1128\/AAC.44.8.2205-2206.2000","volume":"44","author":"ZD Jiang","year":"2000","unstructured":"Jiang ZD, Ke S, Palazzini E, Riopel L, Dupont H. In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob Agents Chemother. 2000;44(8):2205\u20136. https:\/\/doi.org\/10.1128\/AAC.44.8.2205-2206.2000. PMID: 10898704; PMCID: PMC90042.","journal-title":"Antimicrob Agents Chemother"},{"key":"830_CR4","doi-asserted-by":"publisher","unstructured":"DuPont HL, Rifaximin. An antibiotic with important biologic effects. Mini Rev Med Chem. 2015;16(3):200-5. https:\/\/doi.org\/10.2174\/1389557515666150722110201. PMID: 26202192.","DOI":"10.2174\/1389557515666150722110201"},{"issue":"5","key":"830_CR5","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/apt.13928","volume":"45","author":"L Gatta","year":"2017","unstructured":"Gatta L, Scarpignato C. Systematic review with metaanalysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. Aliment Pharmacol Ther. 2017;45(5):604\u201316.","journal-title":"Aliment Pharmacol Ther"},{"key":"830_CR6","doi-asserted-by":"publisher","unstructured":"Hartmann G, Honikel KO, Kn\u00fcsel F, N\u00fcesch J. The specific inhibition of the DNA-directed RNA synthesis by rifamycin. Biochim Biophys Acta. 1967;145(3):843-4. https:\/\/doi.org\/10.1016\/0005-27876790147-5. PMID: 4863911.","DOI":"10.1016\/0005-27876790147-5"},{"key":"830_CR7","doi-asserted-by":"publisher","first-page":"309","DOI":"10.2147\/CEG.S89999","volume":"8","author":"S Soldi","year":"2015","unstructured":"Soldi S, Vasileiadis S, Uggeri F, Campanale MC, Morelli L, Fogli MV, et al. Modulation of the gut microbiota composition by rifaximin in non\u2013constipated irritable bowel syndrome patients: a molecular approach. Clin Exp Gastroenterol. 2015;8:309\u201325. https:\/\/doi.org\/10.2147\/CEG.S89999.","journal-title":"Clin Exp Gastroenterol"},{"key":"830_CR8","doi-asserted-by":"publisher","unstructured":"Xu D, Gao J, Gillilland M 3rd, Wu X, Song I, Kao JY, et al. Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats. Gastroenterology. 2014;146(2):484\u2013e964. https:\/\/doi.org\/10.1053\/j.gastro.2013.10.026.","DOI":"10.1053\/j.gastro.2013.10.026"},{"issue":"5","key":"830_CR9","doi-asserted-by":"publisher","first-page":"e173","DOI":"10.1038\/ctg.2016.32","volume":"7","author":"A Acosta","year":"2016","unstructured":"Acosta A, Camilleri M, Shin A, Nord SL, O\u2019Neill J, Gray AV, et al. Effects of rifaximin on Transit, Permeability, fecal Microbiome, and organic acid excretion in irritable bowel syndrome. Clin Transl Gastroenterol. 2016;7(5):e173. https:\/\/doi.org\/10.1038\/ctg.2016.32.","journal-title":"Clin Transl Gastroenterol"},{"key":"830_CR10","doi-asserted-by":"publisher","unstructured":"Hong KS, Kim JS. Rifaximin for the treatment of acute infectious diarrhea. Therap Adv Gastroenterol. 2011;4(4):227\u2009\u2013\u200935. https:\/\/doi.org\/10.1177\/1756283X11398734 PMID: 21765867; PMCID: PMC3131166.","DOI":"10.1177\/1756283X11398734"},{"key":"830_CR11","doi-asserted-by":"publisher","unstructured":"Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(12):1071-81. https:\/\/doi.org\/10.1056\/NEJMoa0907893. PMID: 20335583.","DOI":"10.1056\/NEJMoa0907893"},{"key":"830_CR12","doi-asserted-by":"publisher","unstructured":"Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP, TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364(1):22\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1004409. PMID: 21208106.","DOI":"10.1056\/NEJMoa1004409"},{"issue":"29","key":"830_CR13","doi-asserted-by":"publisher","first-page":"6638","DOI":"10.3748\/wjg.v22.i29.6638","volume":"22","author":"RH Shayto","year":"2016","unstructured":"Shayto RH, Abou Mrad R, Sharara AI. Use of rifaximin in Gastrointestinal and liver diseases. World J Gastroenterol. 2016;22(29):6638\u201351. https:\/\/doi.org\/10.3748\/wjg.v22.i29.6638. PMID: 27547007; PMCID: PMC4970477.","journal-title":"World J Gastroenterol"},{"issue":"9","key":"830_CR14","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/ja.2014.106","volume":"67","author":"F Calanni","year":"2014","unstructured":"Calanni F, Renzulli C, Barbanti M, Viscomi GC. Rifaximin: beyond the traditional antibiotic activity. J Antibiot (Tokyo). 2014;67(9):667\u201370. https:\/\/doi.org\/10.1038\/ja.2014.106. Epub 2014 Aug 6. PMID: 25095806.","journal-title":"J Antibiot (Tokyo)"},{"issue":"8040","key":"830_CR15","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/s41586-024-08095-4","volume":"635","author":"AM Turner","year":"2024","unstructured":"Turner AM, Li L, Monk IR, Lee JYH, Ingle DJ, Portelli S, et al. Rifaximin prophylaxis causes resistance to the last-resort antibiotic daptomycin. Nature. 2024;635(8040):969\u201377. https:\/\/doi.org\/10.1038\/s41586-024-08095-4. Epub 2024 Oct 23. PMID: 39443798; PMCID: PMC11602712.","journal-title":"Nature"},{"key":"830_CR16","doi-asserted-by":"publisher","unstructured":"Florent, Artru. Virginia Hern\u00e1ndez-Gea, Rifaximin in the spotlight: Are we ready to target the microbiome? JHEP Reports. 2025;7(5):101360, ISSN 2589\u20135559. https:\/\/doi.org\/10.1016\/j.jhepr.2025.101360.","DOI":"10.1016\/j.jhepr.2025.101360"},{"issue":"1","key":"830_CR17","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jinf.2010.11.004","volume":"62","author":"T Valentin","year":"2011","unstructured":"Valentin T, Leitner E, Rohn A, Zollner-Schwetz I, Hoenigl M, Salzer HJ, Krause R. Rifaximin intake leads to emergence of rifampin-resistant Staphylococci. J Infect. 2011;62(1):34\u20138. Epub 2010 Nov 10. PMID: 21073894.","journal-title":"J Infect"},{"issue":"6","key":"830_CR18","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1053\/j.gastro.2016.08.003","volume":"151","author":"A Lembo","year":"2016","unstructured":"Lembo A, Pimentel M, Rao SS, Schoenfeld P, Cash B, Weinstock LB, et al. Repeat treatment with rifaximin is safe and effective in patients with Diarrhea-Predominant irritable bowel syndrome. Gastroenterology. 2016;151(6):1113\u201321. https:\/\/doi.org\/10.1053\/j.gastro.2016.08.003. Epub 2016 Aug 13. PMID: 27528177.","journal-title":"Gastroenterology"},{"issue":"2","key":"830_CR19","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1007\/s10620-019-05804-2","volume":"65","author":"P Feuerstadt","year":"2020","unstructured":"Feuerstadt P, Hong SJ, Brandt LJ. Chronic rifaximin use in cirrhotic patients is associated with decreased rate of C. difficile infection. Dig Dis Sci. 2020;65(2):632\u20138. https:\/\/doi.org\/10.1007\/s10620-019-05804-2. Epub 2019 Aug 22. PMID: 31440997.","journal-title":"Dig Dis Sci"},{"key":"830_CR20","doi-asserted-by":"publisher","unstructured":"Zullo A, Ridola L, Hassan C. Rifaximin therapy and clostridium difficile infection: a note of caution. J Clin Gastroenterol. 2013;47(8):737. https:\/\/doi.org\/10.1097\/MCG.0b013e31828bea4b. PMID: 23507769.","DOI":"10.1097\/MCG.0b013e31828bea4b"},{"key":"830_CR21","doi-asserted-by":"publisher","unstructured":"Pagliari D, Gambassi G, Piccirillo CA, Cianci R. The intricate link among gut immunological niche, microbiota, and xenobiotics in intestinal pathology. Mediators of inflammation. 2017;8390595. https:\/\/doi.org\/10.1155\/2017\/8390595.","DOI":"10.1155\/2017\/8390595"},{"issue":"6","key":"830_CR22","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.tips.2012.03.003","volume":"33","author":"J Cheng","year":"2012","unstructured":"Cheng J, Shah YM, Gonzalez FJ. Pregnane X receptor as a target for treatment of inflammatory bowel disorders. Trends Pharmacol Sci. 2012;33(6):323\u201330. https:\/\/doi.org\/10.1016\/j.tips.2012.03.003. Epub 2012 May 18. PMID: 22609277; PMCID: PMC3368991.","journal-title":"Trends Pharmacol Sci"},{"key":"830_CR23","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/j.bcp.2010.08.022","volume":"80","author":"A Mencarelli","year":"2010","unstructured":"Mencarelli A, Migliorati M, Barbanti M, Cipriani S, Palladino G, Distrutti E, et al. Pregnane-X-receptor mediates the anti-inflammatory activities of rifaximin on detoxification pathways in intestinal epithelial cells. Biochem Pharmacol. 2010;80:1700\u20137. https:\/\/doi.org\/10.1016\/j.bcp.2010.08.022.","journal-title":"Biochem Pharmacol"},{"key":"830_CR24","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.ejphar.2011.06.058","volume":"668","author":"A Mencarelli","year":"2011","unstructured":"Mencarelli A, Renga B, Palladino G, Claudio D, Ricci P, Distrutti E, et al. Inhibition of NF-\u03baB by a PXR-dependent pathway mediates counterregulatory activities of rifaximin on innate immunity in intestinal epithelial cells. Eur J Pharmacol. 2011;668:317\u201324. https:\/\/doi.org\/10.1016\/j.ejphar.2011.06.058.","journal-title":"Eur J Pharmacol"},{"key":"830_CR25","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/01.MIB.0000215092.85116.6c","volume":"12","author":"M Guslandi","year":"2006","unstructured":"Guslandi M, Petrone MC, Testoni PA. Rifaximin for active ulcerative colitis. Inflamm Bowel Dis. 2006;12:335. https:\/\/doi.org\/10.1097\/01.MIB.0000215092.85116.6c.","journal-title":"Inflamm Bowel Dis"},{"issue":"42","key":"830_CR26","doi-asserted-by":"publisher","first-page":"4643","DOI":"10.3748\/wjg.v17.i42.4643","volume":"17","author":"M Guslandi","year":"2011","unstructured":"Guslandi M. Rifaximin in the treatment of inflammatory bowel disease. World J Gastroenterol. 2011;17(42):4643\u20136. https:\/\/doi.org\/10.3748\/wjg.v17.i42.4643. PMID: 22180705; PMCID: PMC3237300.","journal-title":"World J Gastroenterol"},{"key":"830_CR27","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1053\/j.gastro.2005.11.033","volume":"130","author":"TG Dinan","year":"2006","unstructured":"Dinan TG, Quigley EM, Ahmed SM, Scully P, O\u2019Brien S, O\u2019Mahony L, et al. Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology. 2006;130:304\u201311. https:\/\/doi.org\/10.1053\/j.gastro.2005.11.033.","journal-title":"Gastroenterology"},{"key":"830_CR28","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1136\/gut.52.4.523","volume":"52","author":"KA Gwee","year":"2003","unstructured":"Gwee KA, Collins SM, Read NW, Rajnakova A, Deng Y, Graham JC, et al. Increased rectal mucosal expression of Interleukin 1beta in recently acquired post-infectious irritable bowel syndrome. Gut. 2003;52:523\u20136. https:\/\/doi.org\/10.1136\/gut.52.4.523.","journal-title":"Gut"},{"issue":"2","key":"830_CR29","doi-asserted-by":"publisher","first-page":"639","DOI":"10.3892\/ijo.2016.3550","volume":"49","author":"G Esposito","year":"2016","unstructured":"Esposito G, Gigli S, Seguella L, Nobile N, D\u2019Alessandro A, Pesce M, Capoccia E, Steardo L, Cirillo C, Cuomo R, Sarnelli G. Rifaximin, a non-absorbable antibiotic, inhibits the release of pro-angiogenic mediators in colon cancer cells through a pregnane X receptor-dependent pathway. Int J Oncol. 2016;49(2):639\u201345. https:\/\/doi.org\/10.3892\/ijo.2016.3550. Epub 2016 Jun 1. PMID: 27279570.","journal-title":"Int J Oncol"},{"issue":"1","key":"830_CR30","doi-asserted-by":"publisher","first-page":"9815","DOI":"10.1038\/s41598-025-92282-4","volume":"15","author":"T Qiu","year":"2025","unstructured":"Qiu T, Zhu X, Wu J, Hong W, Hu W, Fang T. Mechanisms of rifaximin Inhibition of hepatic fibrosis in mice with metabolic dysfunction associated steatohepatitis through the TLR4\/NF\u03baB pathway. Sci Rep. 2025;15(1):9815. https:\/\/doi.org\/10.1038\/s41598-025-92282-4. PMID: 40118973; PMCID: PMC11928543.","journal-title":"Sci Rep"},{"issue":"3","key":"830_CR31","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1007\/s11596-025-00061-z","volume":"45","author":"S Peng","year":"2025","unstructured":"Peng S, Yin AN, Liao F, Zhao L. Rifaximin inhibits small bowel Angiodysplasia-Associated angiogenesis by attenuating LncRNA-HIF1A-AS2\/miR-153-3p\/HIF-1 \u03b1\/Ang-2 axis. Curr Med Sci. 2025;45(3):574\u201384. https:\/\/doi.org\/10.1007\/s11596-025-00061-z. Epub 2025 Jun 13. PMID: 40512359.","journal-title":"Curr Med Sci"},{"issue":"4","key":"830_CR32","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.jhep.2011.11.013","volume":"56","author":"Q Zhu","year":"2012","unstructured":"Zhu Q, Zou L, Jagavelu K, Simonetto DA, Huebert RC, Jiang ZD, DuPont HL, Shah VH. Intestinal decontamination inhibits TLR4 dependent fibronectin-mediated cross-talk between stellate cells and endothelial cells in liver fibrosis in mice. J Hepatol. 2012;56(4):893\u20139. Epub 2011 Dec 13. PMID: 22173161; PMCID: PMC3307873.","journal-title":"J Hepatol"},{"issue":"6","key":"830_CR33","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.2337\/db07-1403","volume":"57","author":"PD Cani","year":"2008","unstructured":"Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, Burcelin R. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. 2008;57(6):1470\u201381. https:\/\/doi.org\/10.2337\/db07-1403. Epub 2008 Feb 27. PMID: 18305141.","journal-title":"Diabetes"},{"issue":"Pt 2","key":"830_CR34","doi-asserted-by":"publisher","first-page":"113462","DOI":"10.1016\/j.intimp.2024.113462","volume":"143","author":"L Du","year":"2024","unstructured":"Du L, Jiang W, Zhu X, Zhu L, Fan Y, Jiang W. Rifaximin alleviates intestinal barrier disruption and systemic inflammation via the PXR\/NF\u03baB\/MLCK pathway and modulates intestinal lachnospiraceae abundance in heat-stroke mice. Int Immunopharmacol. 2024;143(Pt 2):113462. Epub 2024 Oct 29. PMID: 39461239.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"830_CR35","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12876-023-02690-x","volume":"23","author":"V Ivashkin","year":"2023","unstructured":"Ivashkin V, Shifrin O, Maslennikov R, Poluektova E, Korolev A, Kudryavtseva A, Krasnov G, Benuni N, Barbara G. Eubiotic effect of rifaximin is associated with decreasing abdominal pain in symptomatic uncomplicated diverticular disease: results from an observational cohort study. BMC Gastroenterol. 2023;23(1):82. https:\/\/doi.org\/10.1186\/s12876-023-02690-x. PMID: 36959568; PMCID: PMC10037807.","journal-title":"BMC Gastroenterol"},{"key":"830_CR36","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1002\/puh2.30","volume":"1","author":"D Butler","year":"2022","unstructured":"Butler D, McLoughlin R, Flaherty GT. Travel-related Gastrointestinal diseases: assessment and management. Public Health Chall. 2022;1:e30. https:\/\/doi.org\/10.1002\/puh2.30.","journal-title":"Public Health Chall"},{"key":"830_CR37","doi-asserted-by":"publisher","first-page":"taab099","DOI":"10.1093\/jtm\/taab099","volume":"29","author":"AV Adler","year":"2022","unstructured":"Adler AV, Ciccotti HR, Trivitt SJH, Watson RCJ, Riddle MS. What\u2019s new in travellers\u2019 diarrhoea: updates on Epidemiology, Diagnostics, treatment and Long-Term consequences. J Travel Med. 2022;29:taab099. https:\/\/doi.org\/10.1093\/jtm\/taab099.","journal-title":"J Travel Med"},{"key":"830_CR38","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/jama.2014.17006","volume":"313","author":"R Steffen","year":"2015","unstructured":"Steffen R, Hill DR, DuPont HL. Traveler\u2019s diarrhea a clinical review. JAMA-J Am Med Assoc. 2015;313:71\u201380. https:\/\/doi.org\/10.1001\/jama.2014.17006.","journal-title":"JAMA-J Am Med Assoc"},{"key":"830_CR39","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/j.1708-8305.2011.00538.x","volume":"18","author":"AM Hayat","year":"2011","unstructured":"Hayat AM, Tribble DR, Sanders JW, Faix DJ, Shiau D, Armstrong AW, et al. Knowledge, Attitudes, and practice of travelers\u2019 diarrhea management among frontline providers. J Travel Med. 2011;18:310\u20137. https:\/\/doi.org\/10.1111\/j.1708-8305.2011.00538.x.","journal-title":"J Travel Med"},{"issue":"7","key":"830_CR40","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1080\/14740338.2016.1186639","volume":"15","author":"FR Ponziani","year":"2016","unstructured":"Ponziani FR, Pecere S, Lopetuso L, Scaldaferri F, Cammarota G, Gasbarrini A. Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation. Expert Opin Drug Saf. 2016;15(7):983\u201391. https:\/\/doi.org\/10.1080\/14740338.2016.1186639.","journal-title":"Expert Opin Drug Saf"},{"key":"830_CR41","doi-asserted-by":"publisher","unstructured":"Steffen R, Sack DA, Riopel L, Jiang ZD, St\u00fcrchler M, Ericsson CD, Lowe B, Waiyaki P, White M, DuPont HL. Therapy of travelers\u2019 diarrhea with rifaximin on various continents. Am J Gastroenterol. 2003;98(5):1073-8. https:\/\/doi.org\/10.1111\/j.1572-0241.2003.07283.x. PMID: 12809830.","DOI":"10.1111\/j.1572-0241.2003.07283.x"},{"issue":"11","key":"830_CR42","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1086\/323814","volume":"33","author":"HL DuPont","year":"2001","unstructured":"DuPont HL, Jiang ZD, Ericsson CD, Adachi JA, Mathewson JJ, DuPont MW, et al. Rifaximin versus Ciprofloxacin for the treatment of traveler\u2019s diarrhea: a randomized, double-blind clinical trial. Clin Infect Dis. 2001;33(11):1807\u201315. https:\/\/doi.org\/10.1086\/323814. Epub 2001 Oct 23. PMID: 11692292.","journal-title":"Clin Infect Dis"},{"key":"830_CR43","doi-asserted-by":"publisher","unstructured":"Infante RM, Ericsson CD, Jiang ZD, Ke S, Steffen R, Riopel L, et al. Enteroaggregative Escherichia coli diarrhea in travelers: response to rifaximin therapy. Clin Gastroenterol Hepatol. 2004;2(2):135-8. https:\/\/doi.org\/10.1016\/s1542-35650300322-7. PMID: 15017618.","DOI":"10.1016\/s1542-35650300322-7"},{"key":"830_CR44","doi-asserted-by":"publisher","unstructured":"DuPont HL, Jiang ZD, Okhuysen PC, Ericsson CD, de la Cabada FJ, Ke S, et al. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers\u2019 diarrhea. Ann Intern Med. 2005;142(10):805\u201312. https:\/\/doi.org\/10.7326\/0003-4819-142-10-200505170-00005. Erratum in: Ann Intern Med. 2005;143(3):239. PMID: 15897530.","DOI":"10.7326\/0003-4819-142-10-200505170-00005"},{"key":"830_CR45","doi-asserted-by":"publisher","unstructured":"Martinez-Sandoval F, Ericsson CD, Jiang ZD, Okhuysen PC, Romero JH, Hernandez N, et al. Prevention of travelers\u2019 diarrhea with rifaximin in US travelers to Mexico. J Travel Med. 2010 Mar-Apr;17(2):111-7. https:\/\/doi.org\/10.1111\/j.1708-8305.2009.00385.x. PMID: 20412178.","DOI":"10.1111\/j.1708-8305.2009.00385.x"},{"issue":"1","key":"830_CR46","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12876-020-01336-6","volume":"20","author":"X Zhuang","year":"2020","unstructured":"Zhuang X, Tian Z, Luo M, Xiong L. Short-course rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndrome. BMC Gastroenterol. 2020;20(1):187. https:\/\/doi.org\/10.1186\/s12876-020-01336-6. PMID: 32532214; PMCID: PMC7291629.","journal-title":"BMC Gastroenterol"},{"issue":"5","key":"830_CR47","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s10620-012-2033-7","volume":"57","author":"E Pyleris","year":"2012","unstructured":"Pyleris E, Giamarellos-Bourboulis EJ, Tzivras D, Koussoulas V, Barbatzas C, Pimentel M. The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with irritable bowel syndrome. Dig Dis Sci. 2012;57(5):1321\u20139. https:\/\/doi.org\/10.1007\/s10620-012-2033-7. Epub 2012 Jan 20. PMID: 22262197.","journal-title":"Dig Dis Sci"},{"key":"830_CR48","doi-asserted-by":"publisher","unstructured":"Pimentel M, Cash BD, Lembo A, Wolf RA, Israel RJ, Schoenfeld P. Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity. Dig Dis Sci. 2017;62(9):2455\u20132463. https:\/\/doi.org\/10.1007\/s10620-017-4598-7. Epub 2017 Jun 6. Erratum in: Dig Dis Sci. 2017;62(10):2945. https:\/\/doi.org\/10.1007\/s10620-017-4729-1. PMID: 28589238; PMCID: PMC5561162.","DOI":"10.1007\/s10620-017-4598-7"},{"issue":"3","key":"830_CR49","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.clinthera.2023.01.010","volume":"45","author":"BE Lacy","year":"2023","unstructured":"Lacy BE, Chang L, Rao SSC, Heimanson Z, Sayuk GS. Rifaximin treatment for individual and multiple symptoms of irritable bowel syndrome with diarrhea: an analysis using new end points. Clin Ther. 2023;45(3):198\u2013209. Epub 2023 Mar 14. PMID: 36922331.","journal-title":"Clin Ther"},{"issue":"12","key":"830_CR50","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1093\/jac\/dkq345","volume":"65","author":"S Maccaferri","year":"2010","unstructured":"Maccaferri S, Vitali B, Klinder A, Kolida S, Ndagijimana M, Laghi L, et al. Rifaximin modulates the colonic microbiota of patients with crohn\u2019s disease: an in vitro approach using a continuous culture colonic model system. J Antimicrob Chemother. 2010;65(12):2556\u201365. https:\/\/doi.org\/10.1093\/jac\/dkq345. Epub 2010 Sep 18. PMID: 20852272.","journal-title":"J Antimicrob Chemother"},{"key":"830_CR51","doi-asserted-by":"publisher","first-page":"104936","DOI":"10.1016\/j.phrs.2020.104936","volume":"159","author":"Y Li","year":"2020","unstructured":"Li Y, Hong G, Yang M, Li G, Jin Y, Xiong H, Qian W, Hou X. Fecal bacteria can predict the efficacy of rifaximin in patients with diarrhea-predominant irritable bowel syndrome. Pharmacol Res. 2020;159:104936. https:\/\/doi.org\/10.1016\/j.phrs.2020.104936. Epub 2020 May 26. PMID: 32470562.","journal-title":"Pharmacol Res"},{"issue":"5","key":"830_CR52","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1080\/19490976.2016.1215805","volume":"7","author":"N Zeber-Lubecka","year":"2016","unstructured":"Zeber-Lubecka N, Kulecka M, Ambrozkiewicz F, Paziewska A, Goryca K, Karczmarski J, et al. Limited prolonged effects of rifaximin treatment on irritable bowel syndrome-related differences in the fecal Microbiome and metabolome. Gut Microbes. 2016;7(5):397\u2013413. Epub 2016 Jul 26. PMID: 27662586; PMCID: PMC5046165.","journal-title":"Gut Microbes"},{"key":"830_CR53","doi-asserted-by":"publisher","unstructured":"Sharma BC, Sharma P, Lunia MK, Srivastava S, Goyal R, Sarin SK. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol. 2013;108(9):1458-63. https:\/\/doi.org\/10.1038\/ajg.2013.219. Epub 2013 Jul 23. PMID: 23877348.","DOI":"10.1038\/ajg.2013.219"},{"issue":"8","key":"830_CR54","doi-asserted-by":"publisher","first-page":"767","DOI":"10.3748\/wjg.v18.i8.767","volume":"18","author":"KM Eltawil","year":"2012","unstructured":"Eltawil KM, Laryea M, Peltekian K, Molinari M. Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis. World J Gastroenterol. 2012;18(8):767\u201377. https:\/\/doi.org\/10.3748\/wjg.v18.i8.767. PMID: 22371636; PMCID: PMC3286139.","journal-title":"World J Gastroenterol"},{"issue":"43","key":"830_CR55","doi-asserted-by":"publisher","first-page":"12322","DOI":"10.3748\/wjg.v21.i43.12322","volume":"21","author":"FR Ponziani","year":"2015","unstructured":"Ponziani FR, Gerardi V, Pecere S, D\u2019Aversa F, Lopetuso L, Zocco MA, Pompili M, Gasbarrini A. Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications. World J Gastroenterol. 2015;21(43):12322\u201333. https:\/\/doi.org\/10.3748\/wjg.v21.i43.12322. PMID: 26604640; PMCID: PMC4649116.","journal-title":"World J Gastroenterol"},{"issue":"25","key":"830_CR56","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.3748\/wjg.v23.i25.4491","volume":"23","author":"FR Ponziani","year":"2017","unstructured":"Ponziani FR, Zocco MA, D\u2019Aversa F, Pompili M, Gasbarrini A. Eubiotic properties of rifaximin: disruption of the traditional concepts in gut microbiota modulation. World J Gastroenterol. 2017;23(25):4491\u20139. https:\/\/doi.org\/10.3748\/wjg.v23.i25.4491. PMID: 28740337; PMCID: PMC5504364.","journal-title":"World J Gastroenterol"},{"issue":"10","key":"830_CR57","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.3390\/nu9101124","volume":"9","author":"J Ma","year":"2017","unstructured":"Ma J, Zhou Q, Li H. Gut microbiota and nonalcoholic fatty liver disease: insights on mechanisms and therapy. Nutrients. 2017;9(10):1124. https:\/\/doi.org\/10.3390\/nu9101124.","journal-title":"Nutrients"},{"key":"830_CR58","doi-asserted-by":"publisher","unstructured":"Burkhard PR, Delavelle J, Du Pasquier R, Spahr L. Chronic parkinsonism associated with cirrhosis: a distinct subset of acquired hepatocerebral degeneration. Arch Neurol. 2003;60(4):521-8. https:\/\/doi.org\/10.1001\/archneur.60.4.521. PMID: 12707065.","DOI":"10.1001\/archneur.60.4.521"},{"key":"830_CR59","doi-asserted-by":"publisher","unstructured":"Butterworth RF. Parkinsonism in cirrhosis: pathogenesis and current therapeutic options. Metab Brain Dis. 2013;28(2):261-7. https:\/\/doi.org\/10.1007\/s11011-012-9341-7. Epub 2012 Oct 20. PMID: 23086199.","DOI":"10.1007\/s11011-012-9341-7"},{"issue":"4","key":"830_CR60","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1002\/hep.26364","volume":"58","author":"B Kok","year":"2013","unstructured":"Kok B, Foxton MR, Clough C, Shawcross DL. Rifaximin is an efficacious treatment for the parkinsonian phenotype of hepatic encephalopathy. Hepatology (Baltimore MD). 2013;58(4):1516\u20137. https:\/\/doi.org\/10.1002\/hep.26364.","journal-title":"Hepatology (Baltimore MD)"},{"key":"830_CR61","doi-asserted-by":"publisher","unstructured":"Sousa AL, Salgado P, Alves JE, Silva S, Ferreira S, Magalh\u00e3es M, Y. Uncommon movement disorders in chronic hepatic disease with response to Rifaximin. Tremor other hyperkinet Mov N. 2019;9. https:\/\/doi.org\/10.7916\/tohm.v0.649. PMID: 31413898; PMCID: PMC6691909.","DOI":"10.7916\/tohm.v0.649"},{"issue":"12","key":"830_CR62","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.14309\/ajg.0000000000001997","volume":"117","author":"MJ Villanueva-Millan","year":"2022","unstructured":"Villanueva-Millan MJ, Leite G, Wang J, Morales W, Parodi G, Pimentel ML, et al. Methanogens and hydrogen sulfide producing bacteria guide distinct gut microbe profiles and irritable bowel syndrome subtypes. Am J Gastroenterol. 2022;117(12):2055\u201366. https:\/\/doi.org\/10.14309\/ajg.0000000000001997. Epub 2022 Sep 6. PMID: 36114762; PMCID: PMC9722381.0.","journal-title":"Am J Gastroenterol"},{"key":"830_CR63","doi-asserted-by":"publisher","first-page":"1121435","DOI":"10.3389\/fphar.2023.1121435","volume":"14","author":"H Guo","year":"2023","unstructured":"Guo H, Lu S, Zhang J, Chen C, Du Y, Wang K, Duan L. Berberine and rifaximin effects on small intestinal bacterial overgrowth: study protocol for an investigator-initiated, double-arm, open-label, randomized clinical trial (BRIEF-SIBO study). Front Pharmacol. 2023;14:1121435. https:\/\/doi.org\/10.3389\/fphar.2023.1121435. PMID: 36873985; PMCID: PMC9974661.","journal-title":"Front Pharmacol"},{"issue":"8","key":"830_CR64","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1097\/MCG.0b013e3181c64c90","volume":"44","author":"K Low","year":"2010","unstructured":"Low K, Hwang L, Hua J, Zhu A, Morales W, Pimentel M. A combination of rifaximin and neomycin is most effective in treating irritable bowel syndrome patients with methane on lactulose breath test. J Clin Gastroenterol. 2010;44(8):547\u201350. https:\/\/doi.org\/10.1097\/MCG.0b013e3181c64c90. PMID: 19996983.","journal-title":"J Clin Gastroenterol"},{"key":"830_CR65","doi-asserted-by":"publisher","unstructured":"Prantera C, Lochs H, Grimaldi M, Danese S, Scribano ML, Gionchetti P. & Retic Study Group (Rifaximin-Eir Treatment in Crohn\u2019s Disease). Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn\u2019s disease. Gastroenterology. 2012;201142(3):473\u2013e4814. https:\/\/doi.org\/10.1053\/j.gastro.2011.11.032.","DOI":"10.1053\/j.gastro.2011.11.032"},{"key":"830_CR66","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s10620-009-1111-y","volume":"55","author":"I Shafran","year":"2010","unstructured":"Shafran I, Burgunder P. Adjunctive antibiotic therapy with rifaximin May help reduce crohn\u2019s disease activity. Dig Dis Sci. 2010;55:1079\u201384. https:\/\/doi.org\/10.1007\/s10620-009-1111-y.","journal-title":"Dig Dis Sci"},{"key":"830_CR67","doi-asserted-by":"publisher","unstructured":"Guslandi M. Saccharomyces boulardii plus rifaximin in mesalamine-intolerant ulcerative colitis. J Clin Gastroenterol. 2010;44:385. https:\/\/doi.org\/10.1097\/MCG.0b013e3181cb4233.","DOI":"10.1097\/MCG.0b013e3181cb4233"},{"issue":"6","key":"830_CR68","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/apt.13945","volume":"45","author":"VP Tan","year":"2017","unstructured":"Tan VP, Liu KS, Lam FY, Hung IF, Yuen MF, Leung WK. Randomised clinical trial: rifaximin versus placebo for the treatment of functional dyspepsia. Aliment Pharmacol Ther. 2017;45(6):767\u201376. https:\/\/doi.org\/10.1111\/apt.13945. Epub 2017 Jan 23. PMID: 28112426.","journal-title":"Aliment Pharmacol Ther"},{"key":"830_CR69","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1007\/s10620-021-07149-1","volume":"67","author":"A Shah","year":"2022","unstructured":"Shah A, Gurusamy SR, Hansen T, Callaghan G, Talley NJ, Koloski N, et al. Concomitant irritable bowel syndrome does not influence the response to antimicrobial therapy in patients with functional dyspepsia. Dig Dis Sci. 2022;67:2299\u2013309. https:\/\/doi.org\/10.1007\/s10620-021-07149-1.","journal-title":"Dig Dis Sci"},{"key":"830_CR70","doi-asserted-by":"publisher","unstructured":"Sharara AI, Aoun E, Abdul-Baki H, Mounzer R, Sidani S, Elhajj I. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol. 2006;101(2):326\u2009\u2013\u200933. https:\/\/doi.org\/10.1111\/j.1572-0241.2006.00458.x. PMID: 16454838.","DOI":"10.1111\/j.1572-0241.2006.00458.x"},{"key":"830_CR71","doi-asserted-by":"publisher","unstructured":"Arora U, Sachdeva K, Garg P, Baitha U, Kedia S, Kalaivani M et al. Efficacy of rifaximin in patients with abdominal bloating or distension: a systematic review and meta-analysis. J Clin Gastroenterol. 2024;58(4):360\u2013369. https:\/\/doi.org\/10.1097\/MCG.0000000000001872. PMID: 37310270.","DOI":"10.1097\/MCG.0000000000001872"},{"issue":"1","key":"830_CR72","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1007\/s10620-024-08767-1","volume":"70","author":"MF Garc\u00eda-Cedillo","year":"2025","unstructured":"Garc\u00eda-Cedillo MF, Villegas-Garc\u00eda FU, Arenas-Martinez JS, Ornelas-Arroyo VJ, Yamamoto-Furusho JK, Estrella-Sato LA, et al. Rifaximin-Alpha increases lactase activity in patients with irritable bowel syndrome without constipation and small intestinal bacterial overgrowth. Dig Dis Sci. 2025;70(1):360\u20136. https:\/\/doi.org\/10.1007\/s10620-024-08767-1. Epub 2024 Dec 6. PMID: 39641896.","journal-title":"Dig Dis Sci"},{"key":"830_CR73","doi-asserted-by":"publisher","unstructured":"Cappello G, Marzio L. Rifaximin in patients with lactose intolerance. Dig Liver Dis. 2005;37(5):316-9. https:\/\/doi.org\/10.1016\/j.dld.2004.12.007. PMID: 15843080.","DOI":"10.1016\/j.dld.2004.12.007"},{"issue":"1","key":"830_CR74","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s12974-021-02303-y","volume":"18","author":"H Li","year":"2021","unstructured":"Li H, Xiang Y, Zhu Z, Wang W, Jiang Z, Zhao M, Cheng S, Pan F, Liu D, Ho RCM, Ho CSH. Rifaximin-mediated gut microbiota regulation modulates the function of microglia and protects against CUMS-induced depression-like behaviors in adolescent rat. J Neuroinflammation. 2021;18(1):254. https:\/\/doi.org\/10.1186\/s12974-021-02303-y. PMID: 34736493; PMCID: PMC8567657.","journal-title":"J Neuroinflammation"},{"key":"830_CR75","doi-asserted-by":"publisher","unstructured":"Dalile B, Van Oudenhove L, Vervliet B, Verbeke K. The role of short-chain fatty acids in microbiota-gut-brain communication. Nat Rev Gastroenterol Hepatol. 2019;16(8):461\u2013478. https:\/\/doi.org\/10.1038\/s41575-019-0157-3. PMID: 31123355.","DOI":"10.1038\/s41575-019-0157-3"},{"issue":"9","key":"830_CR76","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1002\/mds.25522","volume":"28","author":"A Fasano","year":"2013","unstructured":"Fasano A, Bove F, Gabrielli M, Petracca M, Zocco MA, Ragazzoni E, et al. The role of small intestinal bacterial overgrowth in parkinson\u2019s disease. Mov Disord. 2013;28(9):1241\u20139. https:\/\/doi.org\/10.1002\/mds.25522.","journal-title":"Mov Disord"},{"issue":"5","key":"830_CR77","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1002\/mds.23566","volume":"26","author":"M Gabrielli","year":"2011","unstructured":"Gabrielli M, Bonazzi P, Scarpellini E, Bendia E, Lauritano EC, Fasano A, et al. Prevalence of small intestinal bacterial overgrowth in parkinson\u2019s disease. Mov Disord. 2011;26(5):889\u201392. https:\/\/doi.org\/10.1002\/mds.23566.","journal-title":"Mov Disord"},{"issue":"21","key":"830_CR78","doi-asserted-by":"publisher","first-page":"3468","DOI":"10.3390\/cells11213468","volume":"11","author":"CT Hong","year":"2022","unstructured":"Hong CT, Chan L, Chen KY, Lee HH, Huang LK, Yang YSH, et al. Rifaximin modifies gut microbiota and attenuates inflammation in parkinson\u2019s disease: preclinical and clinical studies. Cells. 2022;11(21):3468. https:\/\/doi.org\/10.3390\/cells11213468. PMID: 36359864; PMCID: PMC9656351.","journal-title":"Cells"},{"issue":"4","key":"830_CR79","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s11011-014-9507-6","volume":"29","author":"V Ahluwalia","year":"2014","unstructured":"Ahluwalia V, Wade JB, Heuman DM, Hammeke TA, Sanyal AJ, Sterling RK, et al. Enhancement of functional connectivity, working memory and inhibitory control on multi-modal brain MR imaging with rifaximin in cirrhosis: implications for the gut-liver-brain axis. Metab Brain Dis. 2014;29(4):1017\u201325. https:\/\/doi.org\/10.1007\/s11011-014-9507-6. Epub 2014 Mar 4. PMID: 24590688; PMCID: PMC4155029.","journal-title":"Metab Brain Dis"},{"key":"830_CR80","doi-asserted-by":"publisher","first-page":"4479","DOI":"10.1038\/s41598-021-83994-4","volume":"11","author":"D Sometti","year":"2021","unstructured":"Sometti D, Ballan C, Wang H, et al. Effects of the antibiotic rifaximin on cortical functional connectivity are mediated through insular cortex. Sci Rep. 2021;11:4479. https:\/\/doi.org\/10.1038\/s41598-021-83994-4.","journal-title":"Sci Rep"},{"issue":"6","key":"830_CR81","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.3390\/biomedicines10061263","volume":"10","author":"P Leone","year":"2022","unstructured":"Leone P, Mincheva G, Balzano T, Malaguarnera M, Felipo V, Llansola M. Rifaximin improves Spatial learning and memory impairment in rats with liver Damage-Associated neuroinflammation. Biomedicines. 2022;10(6):1263. https:\/\/doi.org\/10.3390\/biomedicines10061263. PMID: 35740285; PMCID: PMC9219896.","journal-title":"Biomedicines"},{"key":"830_CR82","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jad.2023.02.086","volume":"329","author":"S Cheng","year":"2023","unstructured":"Cheng S, Zhu Z, Li H, Wang W, Jiang Z, Pan F, et al. Rifaximin ameliorates depression-like behaviour in chronic unpredictable mild stress rats by regulating intestinal microbiota and hippocampal Tryptophan metabolism. J Affect Disord. 2023;329:30\u201341. Epub 2023 Feb 24. PMID: 36842645.","journal-title":"J Affect Disord"},{"issue":"1","key":"830_CR83","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12986-022-00700-5","volume":"19","author":"C Chojnacki","year":"2022","unstructured":"Chojnacki C, Pop\u0142awski T, Konrad P, Fila M, B\u0142asiak J, Chojnacki J. Antimicrobial treatment improves Tryptophan metabolism and mood of patients with small intestinal bacterial overgrowth. Nutr Metab (Lond). 2022;19(1):66. https:\/\/doi.org\/10.1186\/s12986-022-00700-5. PMID: 36167589; PMCID: PMC9513933.","journal-title":"Nutr Metab (Lond)"},{"issue":"5","key":"830_CR84","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/ajg.2017.46","volume":"112","author":"A Rezaie","year":"2017","unstructured":"Rezaie A, Buresi M, Lembo A, Lin H, McCallum R, Rao S, Schmulson M, Valdovinos M, Zakko S, Pimentel M. Hydrogen and Methane-Based breath testing in Gastrointestinal disorders: the North American consensus. Am J Gastroenterol. 2017;112(5):775\u201384. https:\/\/doi.org\/10.1038\/ajg.2017.46. Epub 2017 Mar 21. PMID: 28323273; PMCID: PMC5418558.","journal-title":"Am J Gastroenterol"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-026-00830-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-026-00830-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-026-00830-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T07:50:43Z","timestamp":1781682643000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-026-00830-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":84,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["830"],"URL":"https:\/\/doi.org\/10.1007\/s43440-026-00830-0","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"assertion":[{"value":"2 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare that no AI \u2013 based tools were used in the preparation, writing, or editing of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"The use of artificial intelligence (AI) tools"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}